New drug cocktail aims to shrink lung tumors before surgery
NCT ID NCT07438600
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining two drugs—sacituzumab tirumotecan and toripalimab—given before surgery can shrink tumors in people with stage II to IIIB non-small cell lung cancer (NSCLC). About 38 participants will receive the drugs intravenously over several weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer left in their lung tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab tirumotecan (a targeted antibody-drug conjugate) combined with toripalimab (an immunotherapy drug)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for certain non-small cell lung cancers, potentially improving tumor shrinkage and long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 38 participants, so results may not apply broadly. The drugs can cause serious side effects like immune-related reactions or low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact